Option chain shows key data for Blackrock Municipal 2030's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Blackrock Municipal 2030.

Blackrock Municipal 2030 (NYSE:BTT) Stock, Option Chain

Blackrock Municipal 2030

Blackrock Municipal 2030 Target Term Trust is a United States-based closed-end management investment company. The investment objective of the company is to provide current income exempt from regular federal income tax and to return $25.00 per common share to holders of common shares. The trust seeks to achieve its investment objectives by investing a majority of its assets in municipal bonds exempt from U.S. federal income taxes.

Cryptocurrency Photo by CMP_NZ on Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

Markets

Movers

$BTC

$BTT

$DOGE

$ETH

$SHIB

$XEC

Major cryptocurrencies surged on Monday evening as Bitcoin’s price rally showed no signs of slowing down. 

Bitcoin Nears $69K, On Verge Of Touching All-Time High — Ethereum, Dogecoin On A Tear: Analyst Predicts King Crypto Hitting $125K Is On The Cards Before 2025

Cryptocurrency Photo by FellowNeko on Shutterstock

$BONK

$FET

$FTM

$LEO

$PEPE

Major cryptocurrencies surged on Sunday evening amid overall optimism in the cryptocurrency market and as FOMO continues to draw in retail investors.

Bitcoin, Ethereum, Dogecoin Rally Amid FOMO: Analyst Predicts $100K On Table For King Crypto, Says &#39;Watch It Like A Hawk&#39;

Bitcoin dips

IBIT

Major cryptocurrencies traded mixed on Thursday, with Bitcoin and Ethereum taking a breather, signaling the onset of the profit-taking season.

Bitcoin, Ethereum Take A Siesta While Dogecoin Surges After February Frenzy: Analyst Sees Apex Crypto Pulling Back To $46K If Correction Occurs

BlackRock Municipal 2030 Target Term Trust

Blackrock Municipal 2030 Target Term Trust

BitTorrent - United States Dollar

Biotest AG

BITECH TECHNOLOGIES CORP by BITECH TECHNOLOGIES CORPORATION

Bitech Technologies Corp

BitTorrent

Better Choice Co Inc

BitTorrent - TrueUSD

BETTER THERAPEUTICS INC by Better Therapeutics, Inc.

Better Therapeutics Inc

Dividends

JBHT

J.B. Hunt Transport Service Has Declared A Regular Quarterly Dividend On Its Common Stock Of $ 0.44 Per Common Share, Which Is A 2.3% Increase Over the Previous Quarterly Dividend. The Dividend Is Payable To Stockholders Of Record On February 7, 2025 And Will Be Paid On February 21, 2025

Nikola Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKLA#NASDAQ">NKLA</a>) shares are trading lower on Thursday, after a report suggesting that <a href="https://www.benzinga.com/movers">bankruptcy may be imminent</a>. According to&nbsp;<a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>, NKLA stock has lost over 94% in the past year.
In a post on X, formerly Twitter, Fred Lambert, the&nbsp;Editor-in-Chief and one of the founding members of Electrek, highlighted that more employees are being let go, and the company has been silent for weeks failing to file production and delivery numbers.
Lambert posted, &#8220;A source (a new source can&#8217;t confirm but has some credibility) says Nikola CEO Stephen Girsky is out, and the bankruptcy filing is already in the hands of lawyers.&#8221;
A flyover of Nikola&#8217;s factory revealed over a hundred trucks sitting idle without batteries, painting a grim picture for the company&#8217;s future, Lambert writes in his post.
Nikola&#8217;s troubles began back in 2020 when short-seller Hindenburg accused it of fraud, and the situation worsened after the <a href="https://www.benzinga.com/news/20/09/17452010/short-seller-compares-nikola-to-theranos-intricate-fraud-built-on-dozens-of-lies">conviction of former CEO</a> Trevor Milton for lying about the company.
Hindenburg published a report labeling the electric car maker as an &#8220;intricate fraud.&#8221; Hindenburg specifically pointed out a video released by Nikola titled &#8220;Nikola One in Motion,&#8221; alleging that the truck was&nbsp;towed to the top of a hill and released instead of being driven at high speed.&nbsp;
Also Read: <a href="https://www.benzinga.com/news/management/25/01/43017547/hindenburg-research-is-closing-up-shop-we-shook-some-empires-that-we-felt-needed-shaking">Hindenburg Research Is Closing Up Shop: &#8216;We Shook Some Empires That We Felt Needed Shaking&#8217;</a>
In December 2023, Trevor Milton, who led Nikola Corporation, was convicted of fraud after a jury found he <a href="https://www.benzinga.com/news/23/12/36289800/nikola-founder-trevor-milton-sentenced-to-4-years-in-prison-for-fraud">had lied persistently about the company</a>.
In April 2024, Milton alleged that the board at Nikola is &#8220;too compromised with rampant <a href="https://www.benzinga.com/news/24/06/39239670/nikola-founder-and-convicted-felon-trevor-milton-files-lawsuit-against-present-chief-legal-officer-d" target="_blank" rel="noreferrer noopener">misconduct and potential fraud.&#8221;</a> He also opined that the&nbsp;<a href="https://www.benzinga.com/news/24/02/37254188/nikolas-fourth-ceo-in-4-years-doubles-up-as-acting-cfo-for-troubled-ev-truck-maker" target="_blank" rel="noreferrer noopener">board must fire current CEO</a>&nbsp;Steve Girsky and those involved in their decisions, as failing to do so might make the company go bankrupt by year-end.
In June last year, Milton&nbsp;also filed a multi-billion derivative lawsuit against the <a href="https://www.benzinga.com/news/24/06/39239670/nikola-founder-and-convicted-felon-trevor-milton-files-lawsuit-against-present-chief-legal-officer-d">company&#8217;s present chief legal officer&nbsp;Britton Worthen,&nbsp;and its directors.</a>
Milton announced the lawsuit via the social media platform&nbsp;LinkedIn. &#8220;Just filed a multi billion dollar derivative malpractice lawsuit against Nikola motor company&#8217;s directors and chief legal officer Britton Worthen. GET READY!&#8221; Milton wrote.
In October, Nikola reported third-quarter revenue of $25.18 million, <a href="https://www.benzinga.com/news/earnings/24/10/41654395/nikola-q3-earnings-revenue-miss-eps-miss-88-fcevs-delivered-fleet-adoption-update-and-more" target="_blank" rel="noreferrer noopener">missing analyst&nbsp;estimates&nbsp;of $37.23 million</a>, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. The EV maker reported a third-quarter adjusted loss of $2.75 per share, missing estimates for a loss of $2.35 per share.
Price Action: NKLA shares are trading lower by 16.2% to $0.98 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43066466/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">Benzinga's ‘Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet</a></li>
</ul>
Photo via Shutterstock.

Equities

Tech

Media

General

NKLA

What's Going On With Nikola Stock On Thursday?

On Thursday, Dr. Reddy's Laboratories Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>) stock is trading lower after the company released third-quarter 2025 earnings.
The pharma company clocked a net income of $165 million, marginally up from $161 million a year ago. Revenue increased from $843 million to $977 million — almost a 16% jump.
The <a target="_blank" href="https://www.drreddys.com/cms/cms/sites/default/files/2025-01/Earnings%20Release_Q3FY25_230125_Final_1.pdf" rel="noreferrer noopener">growth</a> was largely driven by revenues from the recently acquired Nicotine Replacement Therapy (NRT) portfolio, as well as revenues from India and Emerging Markets.
Last year, Haleon plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLN#NYSE">HLN</a>) sold its&nbsp;nicotine replacement therapy&nbsp;business outside of the U.S. to&nbsp;Dr. Reddy's Laboratories SA, a wholly owned subsidiary of&nbsp;Dr. Reddy's Laboratories Limited for 500 million pounds (<a target="_blank" href="https://www.benzinga.com/news/large-cap/24/06/39506878/haleon-to-offload-non-core-nicotine-therapy-business-to-dr-reddys-for-over-600m" rel="noreferrer noopener">around $632 million</a>).
The NRT portfolio consists of brands such as Nicotinell, Nicabate, Habitrol, and Thrive, which are available in gum, lozenge, and patch forms across over 30 markets.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/42819611/cvs-health-aetna-files-lawsuit-against-drugmakers-for-alleged-inflated-generic-drug-prices" rel="noreferrer noopener">CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices</a>
"We delivered double-digit growth aided by our newly acquired NRT business, new launches, and improved operational efficiencies," Co-Chairman &amp; MD, G V Prasad, said.
Global generics revenues reached $850 million (73.75 billion rupees), showing a 17% year-over-year growth; underlying growth excluding NRT is 7%. Revenues from the acquired NRT portfolio, higher volumes and new product launches largely drove growth.
North American sales increased 1% (a sequential decline of 9%) to 33.8 billion rupees. Volume growth coupled with new product launches and favorable forex was offset by price erosion on a YoY basis. The sequential decline was largely due to lower sales of certain products, including Lenalidomide.
Gross Margin at 58.7% (GG: 61.3%, PSAI: 28.6%), a YoY increase of 20 basis points (bps), and a QoQ decline of 91 bps. The YoY increase was primarily due to a favorable product mix and manufacturing overhead leverage, which was partly offset by price erosion. Sequentially, the decline was primarily due to an unfavorable product mix.
Price Action:&nbsp;RDY stock is down 5.80% at $14.22 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43166965/senate-hearings-loom-as-robert-f-kennedy-faces-scrutiny-over-conflicts-of-interest-in-mercks-gardasil-vaccine-litigation" target="_blank" rel="noreferrer noopener">RJK Jr.'s Involvement In Merck Lawsuit Faces Scrutiny Ahead Of Senate Hearing</a></li>
</ul>
Photo by David Pimborough via Shutterstock

Earnings

Large Cap

Health Care

Trading Ideas

Dr Reddy's Laboratories Q3 Earnings: Double-Digit Growth Aided By Newly Acquired Nicotine Replacement Business

Gulfport Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPOR#NYSE">GPOR</a>) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $218.17, a high estimate of $246.00, and a low estimate of $203.00. Marking an increase of 19.22%, the current average surpasses the previous average price target of $183.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1737658873_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Gulfport Energy among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zach Parham</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$208.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Bertrand Donnes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$246.00</td>
<td>$203.00</td>
</tr>
<tr>
<td>Doug Leggate</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$227.00</td>
<td>$164.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$220.00</td>
<td>$174.00</td>
</tr>
<tr>
<td>Tim Rezvan</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$205.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Bertrand Donnes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$203.00</td>
<td>$190.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Gulfport Energy. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Gulfport Energy compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Gulfport Energy's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Gulfport Energy's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/GPOR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Gulfport Energy analyst ratings.</a>
<h2>Get to Know Gulfport Energy Better</h2>
Gulfport Energy Corp is an independent natural gas-weighted exploration and production company focused on the exploration, acquisition and production of natural gas, crude oil and NGL in the United States. It operates through Utica Shale and Scoop properties. The Utica Shale is located in the Appalachian Basin of the United States and Canada. The Scoop (South Central Oklahoma Oil Province) play of Oklahoma is located in the southeast portion of the prolific Anadarko Basin.
<h3>Understanding the Numbers: Gulfport Energy's Finances</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Gulfport Energy's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -4.97% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Energy sector.
Net Margin: Gulfport Energy's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -6.97%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Gulfport Energy's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -0.72%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.47%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Gulfport Energy's debt-to-equity ratio is below the industry average at 0.34, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

GPOR

The Analyst Verdict: Gulfport Energy In The Eyes Of 6 Experts

Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $123.0, a high estimate of $138.00, and a low estimate of $117.00. Witnessing a positive shift, the current average has risen by 2.62% from the previous average price target of $119.86.
<img src="https://www.benzinga.com/files/images/story/2025/1737658864_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Zimmer Biomet Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$138.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$118.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$128.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$118.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$117.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$117.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Zimmer Biomet Holdings. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Zimmer Biomet Holdings compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Zimmer Biomet Holdings's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Zimmer Biomet Holdings's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ZBH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Zimmer Biomet Holdings analyst ratings.</a>
<h2>Unveiling the Story Behind Zimmer Biomet Holdings</h2>
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
<h3>A Deep Dive into Zimmer Biomet Holdings's Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Zimmer Biomet Holdings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 4.03% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Zimmer Biomet Holdings's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 13.66%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Zimmer Biomet Holdings's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.98%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Zimmer Biomet Holdings's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.15%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Zimmer Biomet Holdings's debt-to-equity ratio is below the industry average at 0.52, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 7 Analysts Discuss Zimmer Biomet Holdings Stock

6 analysts have shared their evaluations of Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Charles River and provided 12-month price targets. The average target is $214.5, accompanied by a high estimate of $250.00 and a low estimate of $185.00. A 2.72% drop is evident in the current average compared to the previous average price target of $220.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1737658851_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Charles River among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$190.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Dan Leonard</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$185.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$227.00</td>
<td>$203.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$250.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Ross Muken</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$225.00</td>
<td>$190.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Charles River. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Charles River compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Charles River's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Charles River's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CRL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Charles River analyst ratings.</a>
<h2>About Charles River</h2>
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model &amp; services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery &amp; safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
<h3>Charles River's Economic Impact: An Analysis</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Decline in Revenue: Over the 3 months period, Charles River faced challenges, resulting in a decline of approximately -1.64% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 6.8%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Charles River's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.83%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Charles River's ROA stands out, surpassing industry averages. With an impressive ROA of 0.86%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.73.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Charles River Stock

Providing a diverse range of perspectives from bullish to bearish, 12 analysts have published ratings on Diamondback Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $216.58, along with a high estimate of $256.00 and a low estimate of $190.00. This current average has decreased by 0.77% from the previous average price target of $218.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1737658837_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Diamondback Energy by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Freeman</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$256.00</td>
<td>$237.00</td>
</tr>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$210.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$195.00</td>
<td>$191.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$236.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Doug Leggate</td>
<td>Wolfe Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$232.00</td>
<td>$252.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$219.00</td>
<td>$218.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$207.00</td>
<td>$219.00</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$212.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>John Freeman</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$237.00</td>
<td>$232.00</td>
</tr>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$210.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Subash Chandra</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$195.00</td>
<td>$195.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Diamondback Energy. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Diamondback Energy compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Diamondback Energy's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FANG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Diamondback Energy analyst ratings.</a>
<h2>Unveiling the Story Behind Diamondback Energy</h2>
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2023, the company reported net proven reserves of 2.2 billion barrels of oil equivalent. Net production averaged about 448,000 barrels per day in 2023, at a ratio of 59% oil, 21% natural gas liquids, and 20% natural gas.
<h3>Breaking Down Diamondback Energy's Financial Performance</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Diamondback Energy displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 13.03%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Energy sector.
Net Margin: Diamondback Energy's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 24.91%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Diamondback Energy's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.4%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Diamondback Energy's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.3%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Diamondback Energy's debt-to-equity ratio is below the industry average at 0.35, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FANG

Diamondback Energy Stock: A Deep Dive Into Analyst Perspectives (12 Ratings)

6 analysts have shared their evaluations of Wintrust Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTFC#NASDAQ">WTFC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Wintrust Finl and provided 12-month price targets. The average target is $153.5, accompanied by a high estimate of $157.00 and a low estimate of $150.00. This current average reflects an increase of 6.75% from the previous average price target of $143.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1737658830_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Wintrust Finl. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Karl Shepard</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$152.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Nathan Race</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$156.00</td>
<td>$151.00</td>
</tr>
<tr>
<td>David Long</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$150.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$151.00</td>
</tr>
<tr>
<td>Nicholas Holowko</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$157.00</td>
<td>-</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$151.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Wintrust Finl. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Wintrust Finl compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Wintrust Finl's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Wintrust Finl's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WTFC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Wintrust Finl analyst ratings.</a>
<h2>About Wintrust Finl</h2>
Wintrust Financial Corp is a financial holding company operating in the Chicago metropolitan area and southern Wisconsin through its wholly-owned banking subsidiaries. Wintrust conducts its business through three segments: community banking, specialty finance, and wealth management. Among other services, the company provides community-oriented, personal, and commercial banking, as well as the origination and purchase of residential mortgages for sale into the secondary market. A majority of its banks are banks chartered by the state of Illinois with scores of locations. The company has historically grown through both de novo organization and acquisitions. A majority of its loan portfolio is commercial, mostly in real estate. A majority of Wintrust's net revenue is net interest income.
<h3>Wintrust Finl's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Wintrust Finl's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 3.72% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Wintrust Finl's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 27.93%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Wintrust Finl's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.99% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Wintrust Finl's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.28%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Wintrust Finl's debt-to-equity ratio surpasses industry norms, standing at 0.71. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WTFC

Expert Outlook: Wintrust Finl Through The Eyes Of 6 Analysts

APA's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APA#NYSE">APA</a>) short percent of float has fallen 7.53% since its last report. The company recently reported that it has 22.26 million shares sold short, which is 6.88% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.16 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>APA Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737658823_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for APA has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing APA's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, APA's peer group average for short interest as a percentage of float is 6.54%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into APA's Recent Short Interest

Iron Mountain's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRM#NYSE">IRM</a>) short percent of float has fallen 5.52% since its last report. The company recently reported that it has 7.54 million shares sold short, which is 3.08% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.63 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Iron Mountain Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737658818_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Iron Mountain has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Iron Mountain's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Iron Mountain's peer group average for short interest as a percentage of float is 6.17%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Iron Mountain's Recent Short Interest

Ventas's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) short percent of float has fallen 48.99% since its last report. The company recently reported that it has 10.98 million shares sold short, which is 3.52% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.03 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ventas Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737658813_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ventas has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Ventas's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ventas's peer group average for short interest as a percentage of float is 7.61%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Ventas?

15 analysts have shared their evaluations of Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Halliburton and provided 12-month price targets. The average target is $36.0, accompanied by a high estimate of $43.00 and a low estimate of $30.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 8.79%. 
<img src="https://www.benzinga.com/files/images/story/2025/1737658812_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Halliburton among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keith Mackey</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Kurt Hallead</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$35.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$37.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$30.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>James West</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Lloyd Byrne</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$41.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$33.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$33.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$34.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$34.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Connor Lynagh</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$34.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$43.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>James Rollyson</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$37.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$40.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Kurt Hallead</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Halliburton. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Halliburton compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Halliburton's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Halliburton's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HAL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Halliburton analyst ratings.</a>
<h2>About Halliburton</h2>
Halliburton is North America's largest oilfield service company as measured by market share. Despite industry fragmentation, it holds a leading position in the hydraulic fracturing and completions market, which makes up nearly half of its revenue. It also holds strong positions in other service offerings like drilling and completions fluids, which leverages its expertise in material science, as well as the directional drilling market. While we consider SLB the global leader in reservoir evaluation, we think Halliburton leads in any activity from the reservoir to the wellbore. The firm's innovations have helped multiple producers lower their development costs per barrel of oil equivalent, with techniques that have been homed in over a century of operations.
<h3>A Deep Dive into Halliburton's Financials</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Negative Revenue Trend: Examining Halliburton's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -1.84% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Energy sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 10.02%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 5.63%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Halliburton's ROA excels beyond industry benchmarks, reaching 2.26%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.84, Halliburton adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Halliburton Stands With Analysts

BofA Securities analyst Andrew Obin raised the price target of GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) to $485 from $415 while <a target="_blank" href="https://www.benzinga.com/quote/GEV/analyst-ratings" rel="noreferrer noopener">reiterating the Buy rating</a>.
Yesterday, the company reported revenue growth of 5% year-over-year to $10.559 billion and +9% organically, missing the consensus of $10.78 billion. Earnings per share for the quarter were $1.73, compared to $0.72 a year ago,&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43128325/ge-vernova-mixed-q4-revenue-misses-but-orders-surge-22-amid-strong-electrification-demand" rel="noreferrer noopener">missing the consensus of $2.55</a>.
GE Vernova reaffirmed its 2025 outlook with $36 billion – $37 billion in revenue versus a consensus of $36.88 billion, a high single-digit adjusted EBITDA margin, and&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">$2 billion – $2.5 billion in free cash flow</a>.
The analyst writes that the results were solid. Orders reached $13.2 billion, surpassing the prior $12.2 billion consensus, which likely drove the positive stock reaction.
However, the quarter had some drawbacks, including previously announced increases in R&amp;D and capacity spending. Additionally, management plans to invest $100 million in 2025 to enhance onshore turbine uptime in the Wind segment, adds the analyst.
The analyst says that first-quarter guidance suggests ~$0.3 billion in adjusted EBITDA, below the prior $0.5 billion consensus, mainly due to the timing of cost additions.
The analyst adds that GE Vernova continues to benefit from the electricity and grid investment cycle, which appears to extend beyond 2030.
Obin lowered 2025 adjusted EBITDA forecast to $3.5 billion and sees revenue of $37.1 billion vs. guidance of $36 billion-$37 billion.
For 2026, the analyst projects 6% Y/Y organic revenue growth to $39.3 billion.
For the first quarter of FY25, Obin forecasts 6% Y/Y organic revenue growth to $7.4 billion, with an adjusted EBITDA estimate of $0.3 billion.
Investors can gain exposure to the stock via Invesco S&amp;P Spin-Off ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSD#NYSE">CSD</a>) and TCW Transform Systems ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NETZ#NYSE">NETZ</a>).
Price Action: GEV shares are up 3.91% at $443.79 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43158000/ge-vernova-analysts-boost-their-forecasts-after-strong-q4-results" target="_blank" rel="noreferrer noopener">GE Vernova Analysts Boost Their Forecasts After Strong Q4 Results</a></li>
</ul>
Photo by Ground Picture on Shutterstock.

Analyst Color

Price Target

Reiteration

Engine No. 1 ETF Trust Engine No. 1 Transform Climate ETF

NETZ

GE Vernova's Q4 Was Not Perfect, But Analyst Bumps Up Price Forecast On Continued Orders Strength

WIIM

GATX

GATX shares are trading higher after the company reported better-than-expected Q4 financial results.

Bloom Energy shares are trading higher after JP Morgan raised its price target from $14 to $16.

BofA Securities analyst Omar Dessouky downgraded the shares of Electronic Arts Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) from <a target="_blank" href="https://www.benzinga.com/quote/EA/analyst-ratings" rel="noreferrer noopener">Buy to Neutral</a> and lowered the price forecast from $170 to $130.
The analyst is no longer confident the company can capture enough player engagement and spending to achieve significant growth in the struggling PC/Console gaming market.
Comments regarding Global Football contributing significantly to the $350 million &#8211; 450 million (BofAe) reduction in Live Services bookings suggest that FCUT likely saw a double-digit decline year-over-year, and management anticipates at least another quarter of continued decline.
According to the analyst, the reasons for this downturn remain unclear. Possible explanations include poor execution, seasonal impacts like holiday travel, or structural issues such as a saturated global player base.
Without FC as a key growth driver, the analyst finds it hard to see how EA can sustainably outperform the industry while improving its margins since FC contributes to around 60% of EA&#8217;s operating income, with Ultimate Team likely being one of its highest-margin games.
Yesterday, the company reported preliminary financial results&nbsp;for the third quarter, with revenue of $1.883 billion versus <a target="_blank" href="https://www.benzinga.com/general/gaming/25/01/43146917/electronic-arts-stock-is-sliding-after-the-close-whats-going-on" rel="noreferrer noopener">estimates of $2.507 billion</a>.
The analyst has lowered EPS forecasts for FY25 and FY26 to $6.84 and $6.78 (from $7.86 and $8.65 previously) and cropped the growth estimate for FY26 to just 2%, assuming FC will not experience growth.
Although the analyst is seeing weakness in third-quarter, it is soon to assume that FC is in long-term decline for several reasons, including the recent downturn since November, which seems abrupt and might be due to seasonal factors. Monetization has steadily improved since the launch of FCUT, and the FC player base has remained fairly stable.
The analyst awaits further clarity on the cause of FC&#8217;s weakness in the quarterly earnings call in February.
The price forecast of $130 is based on based on 19x (21x prior) $6.78 FY26 EPS.
Price Action: EA shares are trading lower by 16.9% at $118.28 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43160342/metas-pay-or-consent-policy-faces-fresh-criticism-from-eu-consumer-group" target="_blank" rel="noreferrer noopener">Meta&#8217;s Pay-Or-Consent Policy Faces Fresh Criticism From EU Consumer Group</a></li>
</ul>
Photo via Shutterstock.

Downgrades

Electronic Arts' Growth Questioned: Analyst Downgrades Stock Amid Struggles In Gaming Engagement

LTRPA

TRIP

TripAdvisor shares are trading higher after the company subsidiary Liberty TripAdvisor disclosed in a regulatory filing that another party expressed a non-binding indication of interest to acquire all of the issued and outstanding shares of Tripadvisor.

LOGI

Logitech International shares are trading higher after Morgan Stanley upgraded the stock from Underweight to Equal-Weight and raised its price target from $73 to $92.

Comments

Blackrock Municipal 2030

Blackrock Municipal 2030 (BTT) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga